1. Zimmet P. Globalization coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Intern Mad 2000; 247: 301–10.
2. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS 38. Br Med J 1998; 317: 703–13.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D, for the Multiple Risk Factor Intervention Trial Research Group. Diabetes, other risk factors, and 12–year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434–44.
4. Haffner M, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with 2 diabetes and in nondiabetic subjects with and without prior myocardial infaction. N Engl J Med 1999; 339: 229–34.
5. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease. An Update. Hypertension 2001; 37: 1053–9.
6. Parving H-H. Hypertension and diabetes: the scope of the problem. Blood pressure 2001; 10 (Suppl. 2): 25–31.
7. Cooper M. The prevalence of hypertension in patients with diabetes. In: Hypertension and diabetes (Ed. C.E.Mogensen). Lippincott Williams & Wilkins, London: 2003; 3–9.
8. The ADVANCE Collaborative Group. Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med 2008; 358: 2560–72.
9. Оковитый С.В., Смирнов А.В. Антигипоксанты. Экспер. и клин. фармакол. 2001; 64 (3): 76–80.
10. Фармакотерапия хронических сердечно-сосудистых заболеваний: Руководство. Под ред. акад. РАМН Л.И.Ольбинской. М.: Медицина, 2006.
11. Essop MF, Opie LH. Metabolic therapy for heart failure. Eur Heart J 2004; 25: 1765–8.
12. Cargnoni A, Pasini E, Ceconi C et al. Insight into cytoprotection with metabolic agents. Eur Heart J Supplements 1999, 1: 40–8.
13. Kantor P, Lucien A, Kozak R et al. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long–chain 3–ketoacyl coenzyme A thiolase. Circulation Res 2000; 17: 580–8.
14. Detry JM, Sellier P, Pennaforte D et al., on behalf of the Trimetazidine European Multicenter Study Group. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994; 37: 279–88.
15. Szwed H, Sadowsky Z, Pachocki R et al. Efficacy and safety of trimetazidine in patients with stable angina under b-blocker therapy: TRIMPOL II – Multicenter study. Eur Heart J 1999; 20: 2516.
16. Триметазидин в комбинированной терапии стенокардии напряжения (TACT – Effect of Trimetazidine in patients with stable effort Angina in Combination with existing Therapy). Сердце. 2002; 1: 204–6.
17. Szwed H, Pachocki R, Domzal-Bochelska M et al. The antiischemic effects and tolerability of trimetazidine in coronary diabetic patients. A substudy from TRIMPOL-I. Cardiovasc Drug Ther 1999; 13: 215–20.
18. Szwed H, Pachocki R, Domzal-Bochenska M et al. Efficacite et tolerance de la trimetazidine, antiangoreux hemodynamique dans I'angor d'effort stable. TRIMPOL I une etude multicentrique. Presse Med 2000; 29: 533–8.
19. Маколкин В.И., Осадчий К.К. Эффективность и переносимость триметазидина МВ при лечении стабильной стенокардии напряжения в течение 8 недель (российское исследование ТРИУМФ). Кардиология. 2003; 6: 18–22.
20. Sever PS, Dahlof B, Poulter NR et al., for the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower–than–average cholesterol concentrations, in the Anglo–Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT–LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149–58.
21. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008; 371: 117–25.
22. Оганов Р.Г., Глезер М.Г., Деев А.Д. от имени участников исследования. Результаты Российского исследования ПАРАЛЛЕЛЬ: Программа по выявлению пациентов с неэффективной терапией β-адреноблокаторами и сравнительной оценки эффективности добавления к терапии Предуктала МВ или изосорбида динитрата при стабильной стенокардии. Кардиоваскулярная терапия и профилактика. 2007; 5: 58–65.
23. Всероссийское общество кардиологов. Диагностика и лечение стабильной стенокардии. Российские рекомендации (второй пересмотр) 2008.

Т.Е.Морозова